FDA Grants Breakthrough Status to Bacterial-vs-Viral Blood Test

FDA Grants Breakthrough Status to Blood Test That Tells Bacteria from Virus

The FDA has granted Breakthrough Device designation to MeMed BV Flex, a blood test that rapidly distinguishes bacterial from viral infections using immune-response protein signatures, potentially reducing the antibiotic overprescribing that fuels antimicrobial resistance.

DT Editorial AI

Mar 22, 2026·2 min read·593 words

A Deceptively Simple Clinical Problem

Every day, clinicians face a diagnostic challenge that sounds straightforward but is not: is this patient's infection bacterial or viral? The distinction matters enormously. Bacterial infections require antibiotics; viral infections do not and cannot be treated with them. Prescribing antibiotics for viral infections is not merely ineffective — it actively contributes to antimicrobial resistance by exposing bacteria to sub-therapeutic antibiotic concentrations, selecting for resistant strains that can spread through communities and healthcare settings.

Yet distinguishing the two has historically been difficult at the point of care. Clinical symptoms overlap significantly: both bacterial and viral infections can cause fever, fatigue, elevated white blood cell counts, and the general pattern of systemic illness. Standard laboratory tests — complete blood count, C-reactive protein, procalcitonin — are useful but imprecise; they reflect the magnitude of an inflammatory response rather than its specific cause.

MeMed BV Flex takes a different approach. Instead of measuring a single inflammatory marker, it measures the body's own immune response signature — a panel of host proteins whose relative levels shift in characteristic patterns depending on whether the immune system is responding to a bacterium or a virus.

The Science Behind the Test

MeMed, an Israeli medical diagnostics company, developed the technology by collecting blood samples from thousands of patients with confirmed bacterial or viral infections and analyzing the proteomic patterns associated with each type. The analysis identified a combination of three proteins — tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein — whose combined levels generate a score that accurately classifies infections as bacterial or viral in a majority of clinical presentations.

TRAIL and IP-10 are markedly elevated by viral infections because they are part of the innate immune response specifically triggered by viral nucleic acids. CRP rises with both types but is generally higher in bacterial cases. The ratio and combination of the three markers provides specificity that no single marker achieves on its own, with accuracy rates that in clinical trials have outperformed individual biomarkers and clinical judgment in classifying ambiguous presentations.

Health

Researchers at UC San Francisco and Imperial College London report that one high dose of psilocybin was linked to lasting changes in brain organization, with short-term shifts in neural entropy predicting later gains in-

DT Editorial AI·May 5, 2026·via medicalxpress.com

Health

Researchers analyzing electronic health records from nearly 20 million patients report rapid growth in GLP-1 prescribing, even as many people with severe obesity still receive no treatment and bariatric surgery use slips

DT Editorial AI·May 5, 2026·via medicalxpress.com

Health

A large real-world analysis presented at ASMBS 2026 found that people with obesity and chronic kidney disease who underwent bariatric surgery had markedly lower risks of kidney failure, dialysis, cardiovascular events, и

DT Editorial AI·May 5, 2026·via medicalxpress.com

Health

A University of Michigan study points to a newly identified liver cell type that may offer clues to severe liver disease and future treatment strategies.

What Breakthrough Device Designation Means

FDA's Breakthrough Device Program accelerates development and review for medical devices that provide more effective diagnosis or treatment of serious conditions than currently available alternatives. Designation does not mean the device is approved — it means the FDA commits to more interactive communication with the developer, prioritized review of submissions, and senior agency staff involvement in key decisions.

For MeMed BV Flex, the designation signals that FDA reviewers see the device's potential to address an unmet clinical need of sufficient importance to warrant expedited review. Given that the WHO describes antimicrobial resistance as one of the greatest threats to global health — causing approximately 1.27 million direct deaths annually — a test that reliably reduces inappropriate antibiotic prescribing in emergency departments and primary care settings could have substantial population-level impact.

FDA Grants Breakthrough Status to Blood Test That Tells Bacteria from Virus

A Deceptively Simple Clinical Problem

The Science Behind the Test

Related Articles

Keep Reading

Researchers Point to a Brain-Based Index for Alzheimer’s Risk Patterns Decades Before Old Age

What Breakthrough Device Designation Means

The Stakes

Researchers map Parkinson’s into two major forms and five subgroups

Comments (0)

Phage Cocktail Study Maps a Way Around Resistance in a Hard-to-Treat Lung Infection

A Single Psilocybin Dose Appears to Reshape Brain Activity for Weeks

GLP-1 Prescriptions Surge, but Severe Obesity Still Goes Untreated

Bariatric surgery linked to sharply lower kidney failure and heart risks in chronic kidney disease study

Researchers report a newly identified liver cell that may help explain common liver disease